Legend Biotech (LEGN) Osake Kurssi
Legend Biotech Kurssi
Liikevaihto on kasvanut 60,3 % vuodessa viimeisten 8 vuoden aikana 1,03 Mrd. USD:een. Legend Biotechn nettomarginaali on nyt −28,8 %, noussut −586,4 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 59,00 USD, eli yli nykyhintaa 208,6 %. 23 analyytikosta 17 suosittaa ostoa — kokonaiskonsensus on Osta.
Legend Biotech osakekurssi
Legend Biotech liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Legend Biotech -osakkeesta
Legend Biotech Corp is a leading biopharmaceutical company that specializes in the discovery and development of innovative cell therapies. The company's business model revolves around leveraging its cutting-edge technologies and expertise in genetic engineering to develop personalized and off-the-shelf cell therapies for the treatment of various forms of cancer. By harnessing the power of the immune system, Legend Biotech aims to revolutionize the field of oncology and improve patient outcomes. With a focus on research and development, collaborations, and strategic partnerships, Legend Biotech is dedicated to advancing the future of cell-based immunotherapy and transforming the way cancer is treated.
Legend Biotech Corp is primarily active in the field of biotechnology.
The main competitors of Legend Biotech Corp in the market include prominent biotechnology companies such as Gilead Sciences, Inc., Celgene Corporation, and bluebird bio, Inc.
Legend Biotech Corp is a renowned biopharmaceutical company that focuses on developing cutting-edge cell therapies for patients with cancer. Founded in 2015 and headquartered in Somerset, New Jersey, Legend Biotech Corp is an affiliate of Genscript Biotech Corporation. The company primarily specializes in CAR-T cell therapies and has established a strong global presence. With a strong emphasis on research and development, Legend Biotech Corp has collaborated with numerous academic institutions and industry experts to advance the field of cell therapy. Leveraging its expertise and innovative approach, the company strives to improve the lives of patients worldwide by providing novel and effective treatments for various types of cancer.
Legend Biotech Corp has achieved several significant milestones in its trajectory. Notably, the company successfully completed a Phase 1b/2 clinical trial for its lead product candidate, LCAR-B38M CAR-T cell therapy. This innovative therapy demonstrated compelling clinical responses in patients with relapsed or refractory multiple myeloma, leading to breakthrough status designation by the U.S. FDA. Subsequently, Legend Biotech Corp went on to initiate a global Phase 2 pivotal trial for LCAR-B38M. These achievements showcase the company's dedication to advancing groundbreaking treatments for patients, solidifying its position as a frontrunner in the biotech industry.
Legend Biotech Corp is primarily present in multiple countries and regions. With its headquarters in Somerset, New Jersey, the company has an extensive global presence. It operates in key markets such as the United States, China, and Europe. Legend Biotech Corp has established strategic collaborations and partnerships to extend its reach and leverage market opportunities. By expanding its operations internationally, the company aims to capitalize on the diverse healthcare landscapes and maximize its potential for growth and innovation.
Legend Biotech Corp is a leading biopharmaceutical company that values innovation, integrity, and a patient-centric approach. With a strong corporate philosophy focused on advancing novel cell therapies, Legend Biotech Corp strives to improve the lives of patients around the world. The company is committed to developing cutting-edge treatments for oncology and autoimmune diseases, utilizing its expertise in gene and cell therapies. With a dedication to scientific excellence and a patient-first mindset, Legend Biotech Corp continues to push the boundaries of medical innovation and deliver transformative therapies to those in need.
Analyytikot asettavat tällä hetkellä Legend Biotech-osakkeelle keskimääräisen tavoitehinnan 57,22 USD (mediaani: 59,00 USD), mikä merkitsee +199,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 23 analyytikkoarvioon.
23 analyytikkoa arvioi tällä hetkellä Legend Biotech-osaketta: 17 suosittaa ostoa, 6 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Legend Biotech-yhtiöltä 1,43 Mrd. USD liikevaihtoa ja −0,07 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Legend Biotech-osake noteerataan hintaan 17,06 EUR (19,12 USD).
Legend Biotech-osake (LEGN) on listattuna 4 pörssissä, muun muassa: NASDAQ (LEGN), Frankfurt (9LB.F), München (9LB.MU), Düsseldorf (9LB.DU).
Legend Biotech Corp is an innovative biotechnology company specializing in the development of cell therapies for cancer and autoimmune diseases. The company was founded in 2015 and is headquartered in Somerset, New Jersey. Its business model focuses on discovering and developing therapies for difficult-to-treat diseases, utilizing expertise in gene and cell therapy as well as a proprietary platform for designing, manufacturing, and optimizing therapy products. The company has two main divisions: cancer therapy and autoimmune therapy. In cancer therapy, Legend Biotech Corp focuses on developing immunotherapies that activate the body's immune system to destroy cancer cells, with a promising pipeline of cell therapies for various types of cancer. In autoimmune therapy, the company is developing cell therapies for diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, using a similar approach to the cancer therapy division. The company's product portfolio includes several products in various stages of clinical development, including CAR-T cell therapies for the treatment of Hodgkin's lymphoma and multiple myeloma. Legend Biotech Corp also places a strong emphasis on partnerships and collaborations, working closely with research institutions, universities, and other biotechnology companies to optimize its technology and therapy platforms and develop new products. Overall, the company's business model is characterized by innovative research and development, a focus on discovering new therapies, and close collaboration with partners and other industry stakeholders. The company is well positioned to develop and bring successful cell therapies for cancer and autoimmune diseases to the market.
odotettu liikevaihto Legend Biotech on 1,43 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Legend Biotech on −12,39 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Legend Biotech:n hinta-voitto-suhde (P/E) on tällä hetkellä −285,03. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Legend Biotech-osakkeen arvostusta.
Legend Biotech:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,47. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Legend Biotech-osakkeen arvostuskennuslukuna.
Legend Biotech:n Eulpool-laatuscore on 1/10.
Legend Biotech:n ISIN on US52490G1022. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Legend Biotech:n WKN on A2P5AH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Legend Biotech:n ticker on LEGN. Tämä pörssinoteeraus käytetään Legend Biotech-osakkeiden kauppaan pörssissä.
Legend Biotech osake
Legend Biotech vertaisryhmä
Legend Biotech Ticker
Legend Biotech FIGI
Kaikki tunnusluvut ja syvällinen analyysi Legend Biotech:sta
Meidän osakeanalyysimme Legend Biotech-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Legend Biotech:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: